News Center
  • Adlai Nortye Receives NMPA Approval for Pelareorep Phase III Clinical Trials 2019-03-22 16:45:26
    Adlai Nortye has received a clearance from the National Medical Products Administration (NMPA) of China for initiating the open-label, randomized, multicenter, global phase III clinical trial for pelareorep (AN1004) in combination with paclitaxel in patie

    Read More

  • Adlai Nortye’s Buparlisib Set to Become a Potential Treatment for HNSCC  2019-03-15 18:45:57
    Adlai Nortye Ltd. ("Adlai Nortye"), a global clinical-stage biopharmaceutical company today released the animal model data of Buparlisib (AN2025) at the 7th ICHNO.The data suggests AN2025 could potentially be a treatment option for anti-PD-1 antibodies re

    Read More

  • Adlai Nortye Announces Clinical Collaboration with Merck 2019-01-03 16:26:57
    NORTH BRUNSWICK, New Jersey, -- January 3rd, 2019 -- Adlai Nortye Ltd. ("Adlai Nortye"), a global clinical-stage biopharmaceutical company today announced that it has entered into a clinical collaboration with Merck (known as MSD outside the US and Canada

    Read More

  • Adlai Nortye Opens New US Headquarters 2018-09-27 09:32:00
    Sept. 25, 2018, Adlai Nortye Ltd.announced the official opening of their new USA headquarters today during a ceremony at the Biotechnology Development Center in North Brunswick, New Jersey.

    Read More

  • Adlai Nortye Opens Its First International Site in USA 2018-08-22 15:34:06
    BOSTON, Aug. 8, 2018 , Adlai Nortye Ltd. announced the opening of its first US site in the greater Boston, Massachusetts.

    Read More

  • Adlai Nortye USA Engages Lars E. Birgerson as CDO and President/CEO  2018-08-15 11:17:15
    HANGZHOU, China, Aug. 6, 2018 /PRNewswire/ -- Adlai Nortye Biopharma Co., Ltd. ("Adlai Nortye" or "the Company"), a leading biopharmaceutical company in China, announced that Lars E. Birgerson, M.D., Ph.D., joins the company as Chief Development Officer (

    Read More

  • Adlai Nortye Announces the Publication of the Biomarker Analysis From BERIL-1 2018-07-31 13:52:00
    HANGZHOU, China, July 30, 2018, Adlai Nortye Corporation, a leading biotech company in China, today announced a biomarker analysis publication by the investigators from the phase II study BERIL-1 Buparlisib/Paclitaxel vs Paclitaxel in 2nd Line HNSCC. The

    Read More

  • Adlai Nortye Announce Global License Agreement for Buparlisib (BKM120) 2018-07-23 13:55:35
    Hangzhou, China, July 10, 2018 - Adlai Nortye Biopharma Co., Ltd. (“Adlai Nortye” or “the Company”), a biopharmaceutical company dedicated to discovering and commercializing new drugs in the field of oncology/immuno-oncology, announced today that it has e

    Read More

  • Adlai Nortye Raises $53M in Series B 2018-07-05 11:06:00
    HANGZHOU, China, July 5, 2018, Adlai Nortye announced that it has raised $53 million in a Series B financing round.

    Read More

  • Adlai Nortye terminated a listing on NEEQ  2018-03-20 11:35:00
    Adlai Nortye terminated a listing on NEEQ in Mar, 2018.

    Read More

  • Adlai Nortye Enters into Global License Agreement with Eisai for EP4 Antagonist 2018-01-19 23:26:40
    Adlai Nortye announced that it had entered into a Global License Agreement with Eisai, and will have exclusive worldwide research, development, manufacture and commercialization rights to E7046, excluding Japan and part of Asia other than Mainland China

    Read More

  • Adlai Nortye to Present at the Biotech Showcase™ Annual Conference on January 9 2018-01-02 11:46:18
    Adlai Nortye announced that it will present at Biotech Showcase ™ 2018, to be held January 8–10 during the most important week in healthcare at the Hilton San Francisco Union Square.

    Read More

  • Adlai Nortye and Oncolytics Enter into Regional Licensing Agreement for REOLYSIN 2017-11-20 16:59:58
    Adlai Nortye has entered into a Regional Licensing Agreement with Oncolytics Biotech,a biotech company developing REOLYSIN®, an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems to turn ‘cold’ tumors ‘hot

    Read More

  • Adlai Nortye cooperates with IMM to develop I/O inhibitor 2017-11-03 14:18:17
    October 31, 2017, Adlai Nortye entered into collaboration and co-development with Institute of Materia Medica(IMM), Chinese Academy of Medical Sciences & Peking Union Medical College to develop and commercialize of PD-1/L1 small molecular inhibitor.

    Read More

  • Adlai Nortye signed a cooperation agreement to develop IDO inhibitor 2017-11-01 14:37:00
    September 25, 2017, Adlai Nortye and Suzhou Guokuang Pharmaceutical Inc. signed a cooperation agreement to develop and commercialize IDO small molecular inhibitor.

    Read More